Xiaochao D. Huang

Jiangsu Key Laboratory Of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry And Process Enhancement Technology
Chaigoubu, 223003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Simultaneous Induction of Ferroptosis and Immunogenic Cell Death by TrxR-Targeted Pt(IV) Prodrugs for Chemoimmunotherapy of Triple-Negative Breast Cancer.

Simultaneous Induction of Ferroptosis and Immunogenic Cell Death by TrxR-Targeted Pt(IV) Prodrugs for Chemoimmunotherapy of Triple-Negative Breast Cancer.

Journal: Journal of medicinal chemistry

Published: April 17, 2026

One-dimensional mixed-valence Ce(III)/Ce(IV)-containing arsenotungstate for photocatalytic synthesis of quinazolines.

One-dimensional mixed-valence Ce(III)/Ce(IV)-containing arsenotungstate for photocatalytic synthesis of quinazolines.

Journal: Chemical communications (Cambridge, England)

Published: April 02, 2026

Multifunctional platinum(IV) complexes reverse cisplatin resistance in triple- negative breast cancer via ferroptosis and apoptosis.

Multifunctional platinum(IV) complexes reverse cisplatin resistance in triple- negative breast cancer via ferroptosis and apoptosis.

Journal: Journal of inorganic biochemistry

Published: December 25, 2025

Novel platinum(IV) complexes trigger apoptosis and ferroptosis to conquer cisplatin resistance in triple-negative breast cancer.

Novel platinum(IV) complexes trigger apoptosis and ferroptosis to conquer cisplatin resistance in triple-negative breast cancer.

Journal: Bioorganic chemistry

Published: October 16, 2025

Association between KLK10 gene methylation in female breast tumor tissue and the risk of invasive breast cancer

Association between KLK10 gene methylation in female breast tumor tissue and the risk of invasive breast cancer

Journal: Zhonghua yi xue za zhi

Published: May 21, 2025

Discovery of novel combretastatin A4 derivatives as a microtubule targeting agent capable of inducing HepG-2 cell apoptosis via the mitochondria and ER stress mediated pathway.

Discovery of novel combretastatin A4 derivatives as a microtubule targeting agent capable of inducing HepG-2 cell apoptosis via the mitochondria and ER stress mediated pathway.

Journal: Bioorganic chemistry

Published: April 24, 2025

Discovery of a Novel EF24 Analogue-Conjugated Pt(IV) Complex as Multi-Target Pt(IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance.

Discovery of a Novel EF24 Analogue-Conjugated Pt(IV) Complex as Multi-Target Pt(IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance.

Journal: Journal of medicinal chemistry

Published: February 20, 2025

Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance.

Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance.

Journal: European journal of medicinal chemistry

Published: November 22, 2024

Corrigendum to "Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis" [Eur. J. Med. Chem. 263 (2024) 115968].

Corrigendum to "Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis" [Eur. J. Med. Chem. 263 (2024) 115968].

Journal: European journal of medicinal chemistry

Published: October 22, 2024

Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA.

Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA.

Journal: Bioorganic & medicinal chemistry

Published: September 02, 2024

Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.

Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.

Journal: Journal of medicinal chemistry

Published: May 10, 2024

Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.

Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.

Journal: Journal of medicinal chemistry

Published: April 04, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026